** Shares of Telix Pharmaceuticals TLX.AX rise as much as 3.2% to a record high of A$29.610; last up 2.6%
** The biopharma co says it does not expect business to be affected by the current international trade tariffs levied by the U.S. Government
** Co currently generates most of its revenue from U.S. sales of Illuccix, its prostrate cancer diagnostic drug
** Stock climbed 19.2% in January
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.